Siddiqa Mohammed Abbas Hamza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siddiqa Mohammed Abbas Hamza has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Abozer Y. Elderdery
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia
4 shared publications - Pooi Ling Mok
Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia
3 shared publications - Subbiah Suresh Kumar
Centre for Materials Engineering and Regenerative Medicine, Bharath Institute of Higher Education and Research, Chennai, India
3 shared publications - Gomaa Mostafa-Hedeab
Pharmacology Department and Health Research Unit, Medical College, Jouf University, Skaka, Saudi Arabia
2 shared publications - Abdalbasit Adam Mariod
College of Science, University of Jeddah, Jeddah, Saudi Arabia
1 shared publication - Abdulaziz H. Alhamidi
Clinical Laboratory Sciences Department, College of Applied Medical Science, King Saud University, Riyadh 11451, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 7 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10779
Unveiling the Anticancer Potential: Computational Exploration of Nitrogenated Derivatives of (+)-Pancratistatin as Topoisomerase I Inhibitors
Cancer poses a substantial global health challenge, driving the need for innovative therapeutic solutions that offer improved effectiveness and fewer side effects. Topoisomerase I (Topo I) has emerged as a validated molecular target in the pursuit of developing anticancer drugs due to its critical role in DNA replication and transcription. (+)-Pancratistatin (PST), a naturally occurring compound found in various Amaryllidaceae plants, exhibits promising anticancer properties by inhibiting Topo I activity. However, its clinical utility is hindered by issues related to limited chemical availability and aqueous solubility. To address these challenges, molecular modelling techniques, including virtual screening, molecular docking, molecular mechanics with generalised born and surface area solvation (MM-GBSA) calculations, and molecular dynamics simulations were utilised to evaluate the binding interactions and energetics of PST analogues with Topo I, comparing them with the well-known Topo I inhibitor, Camptothecin. Among the compounds screened for this study, nitrogenated analogues emerged as the most encouraging drug candidates, exhibiting improved binding affinities, favourable interactions with the active site of Topo I, and stability of the protein-ligand complex. Structural analysis pinpointed key molecular determinants responsible for the heightened potency of nitrogenated analogues, shedding light on essential structural modifications for increased activity. Moreover, in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions highlighted favourable drug-like properties and reduced toxicity profiles for the most prominent nitrogenated analogues, further supporting their potential as effective anticancer agents. In summary, this screening study underscores the significance of nitrogenation in augmenting the anticancer efficacy of PST analogues targeting Topo I. The identified lead compounds exhibit significant potential for subsequent experimental validation and optimisation, thus facilitating the development of novel and efficacious anticancer therapeutics with enhanced pharmacological profiles.
- 7 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10779
Open AccessUnveiling the Anticancer Potential: Computational Exploration of Nitrogenated Derivatives of (+)-Pancratistatin as Topoisomerase I Inhibitors
Cancer poses a substantial global health challenge, driving the need for innovative therapeutic solutions that offer improved effectiveness and fewer side effects. Topoisomerase I (Topo I) has emerged as a validated molecular target in the pursuit of developing anticancer drugs due to its critical role in DNA replication and transcription. (+)-Pancratistatin (PST), a naturally occurring compound found in various Amaryllidaceae plants, exhibits promising anticancer properties by inhibiting Topo I activity. However, its clinical utility is hindered by issues related to limited chemical availability and aqueous solubility. To address these challenges, molecular modelling techniques, including virtual screening, molecular docking, molecular mechanics with generalised born and surface area solvation (MM-GBSA) calculations, and molecular dynamics simulations were utilised to evaluate the binding interactions and energetics of PST analogues with Topo I, comparing them with the well-known Topo I inhibitor, Camptothecin. Among the compounds screened for this study, nitrogenated analogues emerged as the most encouraging drug candidates, exhibiting improved binding affinities, favourable interactions with the active site of Topo I, and stability of the protein-ligand complex. Structural analysis pinpointed key molecular determinants responsible for the heightened potency of nitrogenated analogues, shedding light on essential structural modifications for increased activity. Moreover, in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions highlighted favourable drug-like properties and reduced toxicity profiles for the most prominent nitrogenated analogues, further supporting their potential as effective anticancer agents. In summary, this screening study underscores the significance of nitrogenation in augmenting the anticancer efficacy of PST analogues targeting Topo I. The identified lead compounds exhibit significant potential for subsequent experimental validation and optimisation, thus facilitating the development of novel and efficacious anticancer therapeutics with enhanced pharmacological profiles.
- 23 August 2024
- Published by Springer Nature
- p. 289-301
New Discoveries in Toxins from Gram Negative Bacteria Vibrio cholerae
- 23 August 2024
- Published by Springer Nature
- p. 289-301
New Discoveries in Toxins from Gram Negative Bacteria Vibrio cholerae
- Open Access
- 23 February 2023
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 14 (2) , 553-560
A Review of Sudan’s Major Food-Borne Viral and Fungal Diseases
Objective: This review article was conducted to highlight both viral and fungal foodborne situations in Sudan and their health impacts aiming to help health policymakers in introducing strict intervention measures. Method: The review uses up-to-date data via manual screening of the titles and abstracts of retrieved articles using string foodborne diseases in Sudan and foodborne illnesses as keywords to obtain publications from the electronic databases PubMed, Scopus, and Google Scholar from the year 2000-2020 using the publish or perish tool, the databases were reviewed from January to April 2022. Results: Foodborne viruses and Mycotoxins produced by certain fungi; are considered among the top priorities and have become of great concern to the food industry over the last few years because their contamination can occur at any point in the nutritional supply chain besides their serious effects on human health both long and short term. Conclusion: The review on major food borne viral and fungal diseases in Sudan is an important issue to guard against contamination with such micro-organisms and prevent their illnesses.
- 23 February 2023
- Published by Marmara University in Clinical and Experimental Health Sciences
- Vol. 14 (2) , 553-560
Open AccessA Review of Sudan’s Major Food-Borne Viral and Fungal Diseases
Objective: This review article was conducted to highlight both viral and fungal foodborne situations in Sudan and their health impacts aiming to help health policymakers in introducing strict intervention measures. Method: The review uses up-to-date data via manual screening of the titles and abstracts of retrieved articles using string foodborne diseases in Sudan and foodborne illnesses as keywords to obtain publications from the electronic databases PubMed, Scopus, and Google Scholar from the year 2000-2020 using the publish or perish tool, the databases were reviewed from January to April 2022. Results: Foodborne viruses and Mycotoxins produced by certain fungi; are considered among the top priorities and have become of great concern to the food industry over the last few years because their contamination can occur at any point in the nutritional supply chain besides their serious effects on human health both long and short term. Conclusion: The review on major food borne viral and fungal diseases in Sudan is an important issue to guard against contamination with such micro-organisms and prevent their illnesses.
- Open Access
- 26 October 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (21) , 3753
Synthesis, Characterization, and Antimicrobial and Antiproliferative Effects of CuO-TiO2-Chitosan-Escin Nanocomposites on Human Leukemic MOLT4 Cells
Nanocomposites comprised of CuO-TiO2-chitosan-escin, which has adjustable physicochemical properties, provide a solution for therapeutic selectivity in cancer treatment. By controlling the intrinsic signaling primarily through the mitochondrial signaling pathway, we desired nanocomposites with enhanced anticancer activity by containing CuO-TiO2-chitosan-escin. The metal oxides CuO and TiO2, the natural polymer chitosan, and a phytochemical compound escin were combined to form CuO-TiO2-chitosan-escin nanocomposites. The synthesized nanocomposites were confirmed and characterized using FTIR spectroscopy, TEM, and UV-Vis absorption spectroscopy. A human leukemia cell line (MOLT-4) was used to assess the efficacy and selectivity of nanocomposites. Based on a cytotoxicity study, CuO-TiO2-chitosan-escin nanocomposites had inhibition concentrations (IC50) of 13.68, 8.9, and 7.14 µg/mL against human T lymphoblast cells after 24, 48, and 72 h of incubation, respectively. Compared with untreated MOLT-4 cells, CuO-TiO2-chitosan-escin nanocomposite-treated cells significantly increased (p < 0.05) caspase-3, -8, and -9 and decreased the levels of antioxidant enzymes GR, SOD, and GSH. Furthermore, MDA for lipid peroxidase and ROS levels significantly increased (p < 0.05) in the treated cells than in the untreated cells. Remarkably, CuO-TiO2-chitosan-escin nanocomposite-mediated control of cell cycles were mainly achieved through the activation of caspase-3, -8, and -9.
- 26 October 2022
- Published by MDPI AG in Nanomaterials
- Vol. 12 (21) , 3753
Open AccessSynthesis, Characterization, and Antimicrobial and Antiproliferative Effects of CuO-TiO2-Chitosan-Escin Nanocomposites on Human Leukemic MOLT4 Cells
Nanocomposites comprised of CuO-TiO2-chitosan-escin, which has adjustable physicochemical properties, provide a solution for therapeutic selectivity in cancer treatment. By controlling the intrinsic signaling primarily through the mitochondrial signaling pathway, we desired nanocomposites with enhanced anticancer activity by containing CuO-TiO2-chitosan-escin. The metal oxides CuO and TiO2, the natural polymer chitosan, and a phytochemical compound escin were combined to form CuO-TiO2-chitosan-escin nanocomposites. The synthesized nanocomposites were confirmed and characterized using FTIR spectroscopy, TEM, and UV-Vis absorption spectroscopy. A human leukemia cell line (MOLT-4) was used to assess the efficacy and selectivity of nanocomposites. Based on a cytotoxicity study, CuO-TiO2-chitosan-escin nanocomposites had inhibition concentrations (IC50) of 13.68, 8.9, and 7.14 µg/mL against human T lymphoblast cells after 24, 48, and 72 h of incubation, respectively. Compared with untreated MOLT-4 cells, CuO-TiO2-chitosan-escin nanocomposite-treated cells significantly increased (p < 0.05) caspase-3, -8, and -9 and decreased the levels of antioxidant enzymes GR, SOD, and GSH. Furthermore, MDA for lipid peroxidase and ROS levels significantly increased (p < 0.05) in the treated cells than in the untreated cells. Remarkably, CuO-TiO2-chitosan-escin nanocomposite-mediated control of cell cycles were mainly achieved through the activation of caspase-3, -8, and -9.
- RetractedOpen Access
- 28 September 2022
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2022 (1) , 5949086
[Retracted] Synthesis of Zinc Oxide (ZnO)‐Titanium Dioxide (TiO2)‐Chitosan‐Farnesol Nanocomposites and Assessment of Their Anticancer Potential in Human Leukemic MOLT‐4 Cell Line
Leukemia is the most prevalent cancer in children and one of the most common and deadly cancers that affect adults. Several metal oxide nanoparticles, biopolymers, and phytochemicals have been discovered to target cancer cells selectively while inflicting low to no damage to healthy cells. Among the existing nanoparticle synthesis methodologies, biologically synthesized nanoparticles using phytochemicals have emerged as a straightforward, economical, and environmentally sound strategy. The synergistic antitumor potential of ZnO‐TiO2‐chitosan‐farnesol nanocomposites (NCs) against leukemia MOLT‐4 cells was investigated in the current study. After synthesizing the NCs, characterization of the same was carried out using XRD, DLS, FESEM, TEM, PL, EDX, and FTIR spectroscopy. To analyze its anticancer activity, MOLT‐4 cells were cultured and treated at diverse dosages of NCs. The cell viability upon treatment was examined by MTT assay. The morphological and nuclear modifications were observed by dual staining. ROS and MMP levels were observed by DCFH‐DA staining and Rh‐123 dye, respectively. Furthermore, the caspase 3, 8, and 9 levels were examined by performing ELISA. The XRD patterns exhibited a hexagonal structure of the NCs. In the DLS spectrum, the hydrodynamic diameter of the NCs was observed to be 126.2 nm. The electrostatic interface between the ZnO‐TiO2‐chitosan‐farnesol NCs was confirmed by the FTIR spectra. A significant loss of cell viability in a dosage‐dependent trend confirmed the cytotoxic effect of the NCs. An elevated ROS level and MMP depletion suggested apoptosis‐associated cell death via the intrinsic pathway, which was confirmed by elevated expressions of caspase 3, 8, and 9 markers. Thus, the results showed that the synthesized NCs demonstrated a remarkable anticancer potential against leukemic cells and can be potentially valuable in cancer treatments. The findings from this study conclude that this is a new approach for modifying the physicochemical characteristics of ZnO‐TiO2‐chitosan‐farnesol composites to increase their properties and synergistically exhibit anticancer properties in human leukemic cancer cells.
- 28 September 2022
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2022 (1) , 5949086
RetractedOpen Access[Retracted] Synthesis of Zinc Oxide (ZnO)‐Titanium Dioxide (TiO2)‐Chitosan‐Farnesol Nanocomposites and Assessment of Their Anticancer Potential in Human Leukemic MOLT‐4 Cell Line
Leukemia is the most prevalent cancer in children and one of the most common and deadly cancers that affect adults. Several metal oxide nanoparticles, biopolymers, and phytochemicals have been discovered to target cancer cells selectively while inflicting low to no damage to healthy cells. Among the existing nanoparticle synthesis methodologies, biologically synthesized nanoparticles using phytochemicals have emerged as a straightforward, economical, and environmentally sound strategy. The synergistic antitumor potential of ZnO‐TiO2‐chitosan‐farnesol nanocomposites (NCs) against leukemia MOLT‐4 cells was investigated in the current study. After synthesizing the NCs, characterization of the same was carried out using XRD, DLS, FESEM, TEM, PL, EDX, and FTIR spectroscopy. To analyze its anticancer activity, MOLT‐4 cells were cultured and treated at diverse dosages of NCs. The cell viability upon treatment was examined by MTT assay. The morphological and nuclear modifications were observed by dual staining. ROS and MMP levels were observed by DCFH‐DA staining and Rh‐123 dye, respectively. Furthermore, the caspase 3, 8, and 9 levels were examined by performing ELISA. The XRD patterns exhibited a hexagonal structure of the NCs. In the DLS spectrum, the hydrodynamic diameter of the NCs was observed to be 126.2 nm. The electrostatic interface between the ZnO‐TiO2‐chitosan‐farnesol NCs was confirmed by the FTIR spectra. A significant loss of cell viability in a dosage‐dependent trend confirmed the cytotoxic effect of the NCs. An elevated ROS level and MMP depletion suggested apoptosis‐associated cell death via the intrinsic pathway, which was confirmed by elevated expressions of caspase 3, 8, and 9 markers. Thus, the results showed that the synthesized NCs demonstrated a remarkable anticancer potential against leukemic cells and can be potentially valuable in cancer treatments. The findings from this study conclude that this is a new approach for modifying the physicochemical characteristics of ZnO‐TiO2‐chitosan‐farnesol composites to increase their properties and synergistically exhibit anticancer properties in human leukemic cancer cells.
- RetractedOpen Access
- 17 September 2022
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2022 (1) , 9602725
[Retracted] CuO‐TiO2‐Chitosan‐Berbamine Nanocomposites Induce Apoptosis through the Mitochondrial Pathway with the Expression of P53, BAX, and BCL‐2 in the Human K562 Cancer Cell Line
In this study, cells from human Chronic Myelogenous Leukemia (K562) were cultivated with CuO‐TiO2‐Chitosan‐Berbamine nanocomposites. We examined nanocomposites using XRD, DLS, FESEM, TEM, PL, EDAX, and FTIR spectroscopy, as well as MTT for cytotoxicity, and AO/EtBr for apoptotic morphology assessment. The rate of apoptosis and cell cycle arrests was determined using flow cytometry. Flow cytometry was also employed to identify pro‐ and antiapoptotic proteins such as Bcl2, Bad, Bax, P53, and Cyt C. The FTIR spectrum revealed that the CuO‐TiO2‐Chitosan‐Berbamine nanocomposites were electrostatically interlocked. The nanocomposites’ XRD signals revealed a hexagonal shape. In the DLS spectrum, nanocomposites were found to have a hydrodynamic diameter. As a result of their cytotoxic action, nanocomposites displayed concentration‐dependent cytotoxicity. The nanocomposites, like Doxorubicin, caused cell cycle phase arrest in K562 cells. After treatment with IC50 concentrations of CuO‐TiO2‐Chitosan‐Berbamine nanocomposites and Doxorubicin, a substantial percentage of cells were in G2/M stage arrest. Caspase‐3, ‐7, ‐8, ‐9, Bax, Bad, Cyt C, and P53 expression were considerably enhanced in K562 cells, whereas Bcl2 expression was decreased, indicating that these cells may have therapeutic potential against human blood cancer/leukemia‐derived disorders. As a result, the nanocomposites demonstrated outstanding anticancer potential against leukemic cells. CuO‐TiO2‐Chitosan‐Berbamine, according to our findings.
- 17 September 2022
- Published by Wiley in Bioinorganic Chemistry and Applications
- Vol. 2022 (1) , 9602725
RetractedOpen Access[Retracted] CuO‐TiO2‐Chitosan‐Berbamine Nanocomposites Induce Apoptosis through the Mitochondrial Pathway with the Expression of P53, BAX, and BCL‐2 in the Human K562 Cancer Cell Line
In this study, cells from human Chronic Myelogenous Leukemia (K562) were cultivated with CuO‐TiO2‐Chitosan‐Berbamine nanocomposites. We examined nanocomposites using XRD, DLS, FESEM, TEM, PL, EDAX, and FTIR spectroscopy, as well as MTT for cytotoxicity, and AO/EtBr for apoptotic morphology assessment. The rate of apoptosis and cell cycle arrests was determined using flow cytometry. Flow cytometry was also employed to identify pro‐ and antiapoptotic proteins such as Bcl2, Bad, Bax, P53, and Cyt C. The FTIR spectrum revealed that the CuO‐TiO2‐Chitosan‐Berbamine nanocomposites were electrostatically interlocked. The nanocomposites’ XRD signals revealed a hexagonal shape. In the DLS spectrum, nanocomposites were found to have a hydrodynamic diameter. As a result of their cytotoxic action, nanocomposites displayed concentration‐dependent cytotoxicity. The nanocomposites, like Doxorubicin, caused cell cycle phase arrest in K562 cells. After treatment with IC50 concentrations of CuO‐TiO2‐Chitosan‐Berbamine nanocomposites and Doxorubicin, a substantial percentage of cells were in G2/M stage arrest. Caspase‐3, ‐7, ‐8, ‐9, Bax, Bad, Cyt C, and P53 expression were considerably enhanced in K562 cells, whereas Bcl2 expression was decreased, indicating that these cells may have therapeutic potential against human blood cancer/leukemia‐derived disorders. As a result, the nanocomposites demonstrated outstanding anticancer potential against leukemic cells. CuO‐TiO2‐Chitosan‐Berbamine, according to our findings.